S-1 Filing

SOLENO THERAPEUTICS INC CIK: 1484565

Filing Information

Form Type	S-1
Accession Number	`0001564590-19-010146`
Period End Date	20181231
Filing Date	20190329
Fiscal Year	N/A
Fiscal Period	N/A
XBRL Instance	slno-20190223.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 60 Income Statement 50 Cash Flow Statement 71 Stockholders Equity 16

Balance Sheet 60 line items

Line Item	Tag	Value	Unit	Period
Preferred stock par value (in dollars per share)	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred stock par value (in dollars per share)	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred stock shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Preferred stock shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	100.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	100.00M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	31.76M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	19.24M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	19.24M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	31.76M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$17.10M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$23.10M	USD	Point-in-time
Restricted cash	`RestrictedCashAndCashEquivalentsAtCarryingValue`	$35.00K	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$529.00K	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$343.00K	USD	Point-in-time
Due from related party	`DueFromRelatedPartiesCurrent`	$64.00K	USD	Point-in-time
Minority interest investment in former subsidiary	`MinorityInterestInvestmentInSubsidiary`	$978.00K	USD	Point-in-time
Current assets held for sale	`AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent`	$516.00K	USD	Point-in-time
Total current assets	`AssetsCurrent`	$17.99M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$24.67M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$23.00K	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$12.00K	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$126.00K	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$18.47M	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$20.41M	USD	Point-in-time
Long-term assets held for sale	`DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent`	$466.00K	USD	Point-in-time
Total assets	`Assets`	$39.02M	USD	Point-in-time
Total assets	`Assets`	$43.15M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$633.00K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$934.00K	USD	Point-in-time
Accrued compensation and other current liabilities	`AccruedLiabilitiesAndOtherLiabilities`	$973.00K	USD	Point-in-time
Accrued compensation and other current liabilities	`AccruedLiabilitiesAndOtherLiabilities`	$943.00K	USD	Point-in-time
Current liabilities held for sale	`LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent`	$127.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.73M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.88M	USD	Point-in-time
Contingent liability for Essentialis purchase price	`AssetAcquisitionContingentConsiderationLiabilityNoncurrent`	$5.08M	USD	Point-in-time
Contingent liability for Essentialis purchase price	`AssetAcquisitionContingentConsiderationLiabilityNoncurrent`	$5.65M	USD	Point-in-time
Other liabilities	`OtherLiabilitiesNoncurrent`	$13.00K	USD	Point-in-time
Long-term liabilities held for sale	`LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent`	$225.00K	USD	Point-in-time
Total liabilities	`Liabilities`	$13.08M	USD	Point-in-time
Total liabilities	`Liabilities`	$12.21M	USD	Point-in-time
Total liabilities	`Liabilities`	$12.74M	USD	Point-in-time
Total liabilities	`Liabilities`	$16.70M	USD	Point-in-time
Commitments and contingencies (Note 7)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies (Note 7)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Common stock	`CommonStockValue`	$32.00K	USD	Point-in-time
Common stock	`CommonStockValue`	$19.00K	USD	Point-in-time
Additional paid-in-capital	`AdditionalPaidInCapitalCommonStock`	$157.41M	USD	Point-in-time
Additional paid-in-capital	`AdditionalPaidInCapitalCommonStock`	$140.50M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-117.50M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-124.56M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-127.03M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-113.70M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$26.82M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$30.41M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$3.44M	USD	Point-in-time
Total liabilities and stockholders equity	`LiabilitiesAndStockholdersEquity`	$43.15M	USD	Point-in-time
Total liabilities and stockholders equity	`LiabilitiesAndStockholdersEquity`	$39.02M	USD	Point-in-time

Income Statement 50 line items

Line Item	Tag	Value	Unit	Period
Research and development	`ResearchAndDevelopmentExpense`	$3.07M	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$7.18M	USD	Annual
Sales and marketing	`SellingAndMarketingExpense`	$26.00K	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$6.56M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$6.58M	USD	Annual
Change in fair value of contingent consideration	`AssetAcquisitionContingentConsiderationChangeInFairValue`	$2.49M	USD	Annual
Change in fair value of contingent consideration	`AssetAcquisitionContingentConsiderationChangeInFairValue`	$567.00K	USD	Annual
Total operating expenses	`OperatingExpenses`	$12.17M	USD	Annual
Total operating expenses	`OperatingExpenses`	$14.30M	USD	Annual
Operating loss	`OperatingIncomeLoss`	$-12.17M	USD	Annual
Operating loss	`OperatingIncomeLoss`	$-14.30M	USD	Annual
Cease-use income	`GainLossOnContractTermination`	$4.00K	USD	Annual
Cease-use income	`GainLossOnContractTermination`	$6.00K	USD	Annual
Change in fair value of warrants liabilities	`FairValueAdjustmentOfWarrants`	$3.25M	USD	1 Quarter
Change in fair value of warrants liabilities	`FairValueAdjustmentOfWarrants`	$-163.00K	USD	1 Quarter
Change in fair value of warrants liabilities	`FairValueAdjustmentOfWarrants`	$3.09M	USD	2 Qtrs
Change in fair value of warrants liabilities	`FairValueAdjustmentOfWarrants`	$-522.00K	USD	Annual
Change in fair value of warrants liabilities	`FairValueAdjustmentOfWarrants`	$685.00K	USD	Annual
Gain on deconsolidation of former subsidiary	`DeconsolidationGainOrLossAmount`	$1.99M	USD	Annual
Interest and other expense, net	`OtherNonoperatingIncomeExpense`	$-590.00K	USD	Annual
Interest and other expense, net	`OtherNonoperatingIncomeExpense`	$-62.00K	USD	Annual
Total other income (expense)	`NonoperatingIncomeExpense`	$2.46M	USD	Annual
Total other income (expense)	`NonoperatingIncomeExpense`	$-1.27M	USD	Annual
Total other income (expense)	`NonoperatingIncomeExpense`	$-3.22M	USD	1 Quarter
Total other income (expense)	`NonoperatingIncomeExpense`	$-3.04M	USD	2 Qtrs
Total other income (expense)	`NonoperatingIncomeExpense`	$185.00K	USD	1 Quarter
Loss from continuing operations before provision for income tax benefit	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-13.44M	USD	Annual
Loss from continuing operations before provision for income tax benefit	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-11.84M	USD	Annual
Provision for income tax benefit from continuing operations	`IncomeTaxExpenseBenefit`	-	USD	Annual
Provision for income tax benefit from continuing operations	`IncomeTaxExpenseBenefit`	$-1.65M	USD	Annual
Loss from continuing operations	`IncomeLossFromContinuingOperations`	$-11.84M	USD	Annual
Loss from continuing operations	`IncomeLossFromContinuingOperations`	$-11.79M	USD	Annual
Operating loss	`DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax`	$-1.49M	USD	Annual
Operating loss	`DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax`	$-3.40M	USD	Annual
Other expense	`DisposalGroupIncludingDiscontinuedOperationIncomeExpenses`	$-194.00K	USD	Annual
Total	`IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity`	$-3.59M	USD	Annual
Total	`IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity`	$-1.49M	USD	Annual
Net loss	`NetIncomeLoss`	$-15.38M	USD	Annual
Net loss	`NetIncomeLoss`	$-13.34M	USD	Annual
Loss per common share from continuing operations, basic and diluted	`IncomeLossFromContinuingOperationsPerBasicAndDilutedShare`	$-0.56	USD	Annual
Loss per common share from continuing operations, basic and diluted	`IncomeLossFromContinuingOperationsPerBasicAndDilutedShare`	$-1.31	USD	Annual
Loss per common share from discontinued operations, basic and diluted	`DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare`	$-0.40	USD	Annual
Loss per common share from discontinued operations, basic and diluted	`DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare`	$-0.07	USD	Annual
Net loss per common share, basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.35	USD	1 Quarter
Net loss per common share, basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.19	USD	1 Quarter
Net loss per common share, basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.54	USD	2 Qtrs
Net loss per common share, basic and diluted	`EarningsPerShareBasicAndDiluted`	$-1.71	USD	Annual
Net loss per common share, basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.64	USD	Annual
Weighted-average common shares outstanding used to calculate basic and diluted net loss per common share	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	20.98M	shares	Annual
Weighted-average common shares outstanding used to calculate basic and diluted net loss per common share	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	8.98M	shares	Annual

Cash Flow Statement 71 line items

Line Item	Tag	Value	Unit	Period
Net loss	`ProfitLoss`	$-15.38M	USD	Annual
Net loss	`ProfitLoss`	$-13.34M	USD	Annual
Loss from discontinued operations	`IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity`	$-3.59M	USD	Annual
Loss from discontinued operations	`IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity`	$-1.49M	USD	Annual
Loss from continuing operations	`IncomeLossFromContinuingOperations`	$-11.84M	USD	Annual
Loss from continuing operations	`IncomeLossFromContinuingOperations`	$-11.79M	USD	Annual
Depreciation and amortization	`DepreciationAndAmortization`	$1.61M	USD	Annual
Depreciation and amortization	`DepreciationAndAmortization`	$1.96M	USD	Annual
Stock-based compensation expense	`ShareBasedCompensation`	$988.00K	USD	Annual
Stock-based compensation expense	`ShareBasedCompensation`	$880.00K	USD	Annual
Income tax benefit	`IncreaseDecreaseInIncomeTaxes`	$-1.65M	USD	Annual
Board fees paid with common stock	`OtherNoncashExpense`	$278.00K	USD	Annual
Board fees paid with common stock	`OtherNoncashExpense`	$275.00K	USD	Annual
Change in fair value of stock warrants	`FairValueAdjustmentOfWarrants`	$3.25M	USD	1 Quarter
Change in fair value of stock warrants	`FairValueAdjustmentOfWarrants`	$-163.00K	USD	1 Quarter
Change in fair value of stock warrants	`FairValueAdjustmentOfWarrants`	$3.09M	USD	2 Qtrs
Change in fair value of stock warrants	`FairValueAdjustmentOfWarrants`	$-522.00K	USD	Annual
Change in fair value of stock warrants	`FairValueAdjustmentOfWarrants`	$685.00K	USD	Annual
Change in fair value of contingent consideration	`AssetAcquisitionContingentConsiderationChangeInFairValue`	$2.49M	USD	Annual
Change in fair value of contingent consideration	`AssetAcquisitionContingentConsiderationChangeInFairValue`	$567.00K	USD	Annual
Non-cash expense of issuing shares to Aspire Capital	`NoncashExpenseOnSharesIssued`	$602.00K	USD	Annual
Gain on deconsolidation of former subsidiary	`DeconsolidationGainOrLossAmount`	$1.99M	USD	Annual
Operating loss of minority interest investment	`IncomeLossFromEquityMethodInvestments`	$-160.00K	USD	Annual
Prepaid expenses, other current assets and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$97.00K	USD	Annual
Prepaid expenses, other current assets and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$60.00K	USD	Annual
Due from related party	`IncreaseDecreaseInDueFromRelatedParties`	$64.00K	USD	Annual
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$249.00K	USD	Annual
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$191.00K	USD	Annual
Accrued compensation and other current liabilities	`IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities`	$-78.00K	USD	Annual
Accrued compensation and other current liabilities	`IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities`	$-43.00K	USD	Annual
Other long-term liabilities	`IncreaseDecreaseInOtherNoncurrentLiabilities`	$-40.00K	USD	Annual
Net cash used in continuing operating activities	`NetCashProvidedByUsedInOperatingActivitiesContinuingOperations`	$-6.92M	USD	Annual
Net cash used in continuing operating activities	`NetCashProvidedByUsedInOperatingActivitiesContinuingOperations`	$-10.32M	USD	Annual
Net cash used in discontinued operating activities	`CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations`	$-3.03M	USD	Annual
Net cash used in discontinued operating activities	`CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations`	$-1.36M	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-11.68M	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-9.95M	USD	Annual
Costs of Essentialis acquisition paid	`PaymentsToAcquireAssetsInvestingActivities`	$573.00K	USD	Annual
Security deposit on sublease	`ProceedsFromSecurityDepositOnSublease`	$13.00K	USD	Annual
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$8.00K	USD	Annual
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$2.00K	USD	Annual
Net cash used in continuing investing activities	`NetCashProvidedByUsedInInvestingActivitiesContinuingOperations`	$-562.00K	USD	Annual
Net cash used in continuing investing activities	`NetCashProvidedByUsedInInvestingActivitiesContinuingOperations`	$-8.00K	USD	Annual
Net cash (used in) provided by discontinued investing activities	`CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations`	$-172.00K	USD	Annual
Net cash (used in) provided by discontinued investing activities	`CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations`	$716.00K	USD	Annual
Net cash (used in) provided by investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-180.00K	USD	Annual
Net cash (used in) provided by investing activities	`NetCashProvidedByUsedInInvestingActivities`	$154.00K	USD	Annual
Proceeds from issuance of common stock	`ProceedsFromIssuanceOfCommonStock`	$10.00M	USD	Annual
Proceeds from sale of common stock and common stock warrants	`ProceedsFromSaleOfCommonStockAndCommonStockWarrants`	$16.50M	USD	Annual
Proceeds from sale of common stock and common stock warrants	`ProceedsFromSaleOfCommonStockAndCommonStockWarrants`	$15.01M	USD	Annual
Cash paid for the issuance of common stock and common stock warrants	`CashPaidForTheIssuanceOfCommonStockAndCommonStockWarrants`	$198.00K	USD	Annual
Cash paid for the issuance of common stock and common stock warrants	`CashPaidForTheIssuanceOfCommonStockAndCommonStockWarrants`	$1.06M	USD	Annual
Net cash provided by continuing financing activities	`NetCashProvidedByUsedInFinancingActivitiesContinuingOperations`	$23.95M	USD	Annual
Net cash provided by continuing financing activities	`NetCashProvidedByUsedInFinancingActivitiesContinuingOperations`	$16.30M	USD	Annual
Net cash provided by discontinued financing activities	`CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations`	$1.52M	USD	Annual
Net cash provided by discontinued financing activities	`CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations`	$225.00K	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$24.17M	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$17.83M	USD	Annual
Net increase in cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$14.37M	USD	Annual
Net increase in cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$5.96M	USD	Annual
Cash, cash equivalents and restricted cash, beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$2.76M	USD	Point-in-time
Cash, cash equivalents and restricted cash, beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$17.14M	USD	Point-in-time
Cash, cash equivalents and restricted cash, beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$23.10M	USD	Point-in-time
Cash, cash equivalents and restricted cash, end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$2.76M	USD	Point-in-time
Cash, cash equivalents and restricted cash, end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$17.14M	USD	Point-in-time
Cash, cash equivalents and restricted cash, end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$23.10M	USD	Point-in-time
Issuance of common stock in Essentialis acquisition	`StockIssued1`	$17.25M	USD	Annual
Contingent consideration of Essentialis acquisition	`NoncashOrPartNoncashAcquisitionContingentConsideration`	$2.59M	USD	Annual
Accrued liability for cost of issuing common stock	`AccruedLiabilityForCostOfIssuingCommonStock`	$52.00K	USD	Annual
Warrants issued in connection with sale of common stock	`WarrantsIssuedInConnectionWithSaleOfCommonStock`	$582.00K	USD	Annual
Warrants issued in connection with sale of common stock	`WarrantsIssuedInConnectionWithSaleOfCommonStock`	$4.19M	USD	Annual

Stockholders Equity 16 line items

Line Item	Tag	Value	Unit	Period
Less transaction costs	`AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts`	$250.00K	USD	Annual
Less transaction costs	`AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts`	$1.17M	USD	Annual
Balances at beginning	`StockholdersEquity`	$26.82M	USD	Point-in-time
Balances at beginning	`StockholdersEquity`	$30.41M	USD	Point-in-time
Balances at beginning	`StockholdersEquity`	$3.44M	USD	Point-in-time
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$1.00M	USD	Annual
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$829.00K	USD	Annual
Issuance of restricted common stock for bonuses	`IssuanceOfRestrictedCommonStockForBonusesValue`	$159.00K	USD	Annual
Issuance of common stock to board members in lieu of cash payments for quarterly board fees	`StockIssuedDuringPeriodValueIssuedForServices`	$275.00K	USD	Annual
Issuance of common stock to board members in lieu of cash payments for quarterly board fees	`StockIssuedDuringPeriodValueIssuedForServices`	$278.00K	USD	Annual
Issuance of shares to Aspire Capital in lieu of commitment fees	`IssuanceOfStockAndWarrantsForServicesOrClaims`	$602.00K	USD	Annual
Net loss	`NetIncomeLoss`	$-15.38M	USD	Annual
Net loss	`NetIncomeLoss`	$-13.34M	USD	Annual
Balances at ending	`StockholdersEquity`	$26.82M	USD	Point-in-time
Balances at ending	`StockholdersEquity`	$30.41M	USD	Point-in-time
Balances at ending	`StockholdersEquity`	$3.44M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.